| Melissa Swierad, APRN, CNP | |
|
1000 N Westmoreland Rd # Level1, Lake Forest, IL 60045-1658 | |
| (847) 534-3278 | |
| (847) 535-8590 |
| Full Name | Melissa Swierad |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 1000 N Westmoreland Rd # Level1, Lake Forest, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588041891 | NPI | - | NPPES |
| 209012706 | Medicaid | IL |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwestern Lake Forest Hospital | Lake forest, IL | Hospital |
| Northwestern Memorial Hospital | Chicago, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwestern Medical Faculty Foundation | 4587576814 | 3255 |
News Archive
Screening all newborns for excessive bilirubin in the blood can significantly decrease the incidence of severe jaundice which, in extreme cases, can lead to seizures and brain damage, according to researchers at UCSF Children's Hospital and Kaiser Permanente's Division of Research in Oakland, CA.
Doctors are often deluged by signals from charts, test results, and other metrics to keep track of. It can be difficult to integrate and monitor all of these data for multiple patients while making real-time treatment decisions, especially when data is documented inconsistently across hospitals.
Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.
Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.
Flu season will look different this year, as the country grapples with a coronavirus pandemic that has killed more than 172,000 people. Many Americans are reluctant to visit a doctor's office and public health officials worry people will shy away from being immunized.
› Verified 4 days ago
| Entity Name | Northwestern Medical Faculty Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346235314 PECOS PAC ID: 4587576814 Enrollment ID: O20031105000541 |
News Archive
Screening all newborns for excessive bilirubin in the blood can significantly decrease the incidence of severe jaundice which, in extreme cases, can lead to seizures and brain damage, according to researchers at UCSF Children's Hospital and Kaiser Permanente's Division of Research in Oakland, CA.
Doctors are often deluged by signals from charts, test results, and other metrics to keep track of. It can be difficult to integrate and monitor all of these data for multiple patients while making real-time treatment decisions, especially when data is documented inconsistently across hospitals.
Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.
Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.
Flu season will look different this year, as the country grapples with a coronavirus pandemic that has killed more than 172,000 people. Many Americans are reluctant to visit a doctor's office and public health officials worry people will shy away from being immunized.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Swierad, APRN, CNP 1000 N Westmoreland Rd # Level1, Lake Forest, IL 60045-1658 Ph: (847) 534-3278 | Melissa Swierad, APRN, CNP 1000 N Westmoreland Rd # Level1, Lake Forest, IL 60045-1658 Ph: (847) 534-3278 |
News Archive
Screening all newborns for excessive bilirubin in the blood can significantly decrease the incidence of severe jaundice which, in extreme cases, can lead to seizures and brain damage, according to researchers at UCSF Children's Hospital and Kaiser Permanente's Division of Research in Oakland, CA.
Doctors are often deluged by signals from charts, test results, and other metrics to keep track of. It can be difficult to integrate and monitor all of these data for multiple patients while making real-time treatment decisions, especially when data is documented inconsistently across hospitals.
Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.
Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.
Flu season will look different this year, as the country grapples with a coronavirus pandemic that has killed more than 172,000 people. Many Americans are reluctant to visit a doctor's office and public health officials worry people will shy away from being immunized.
› Verified 4 days ago
Katie L Konopacz, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1000 N Westmoreland Rd # B, Lake Forest, IL 60045 Phone: 847-535-3278 | |
Melissa Hilb, CPNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 900 N Westmoreland Rd, Suite 110, Lake Forest, IL 60045 Phone: 847-295-1220 Fax: 847-295-1255 | |
Melissa Katelyn Battista, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 555 N Sheridan Rd, Lake Forest, IL 60045 Phone: 847-735-5050 Fax: 847-735-6284 | |
Armando Comas, APRN, CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1000 N Westmoreland Rd, Lake Forest, IL 60045 Phone: 847-535-6150 Fax: 847-535-7801 | |
Mrs. Cynthia H. Leaker, MSN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 660 N Westmoreland Rd, Lake Forest Hospital Emergency Department, Lake Forest, IL 60045 Phone: 312-259-9943 | |
Andrea C Komsri, APRN, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1000 N Westmoreland Rd, Pavilion B, Level 1, Lake Forest, IL 60045 Phone: 847-534-3278 | |
Carly Cooper, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1000 N Westmoreland Rd, Lake Forest, IL 60045 Phone: 847-234-5600 |